Literature DB >> 18220701

Leukocyte influx in atherosclerosis.

Elena Galkina1, Klaus Ley.   

Abstract

Atherosclerosis is a chronic inflammatory disease of the arterial wall and an increasing body of evidence suggests that the immune system actively participates in the initiation, progression and persistence of atherosclerosis. Different types of leukocytes such as T and B lymphocytes, natural killer cells (NK) and NKT cells, macrophages, dendritic cells and mast cells have been found within atherosclerosis-prone aortas. The mechanisms of monocyte recruitment have been partially characterized and involve P-selectin, E-selectin, VCAM-1, ICAM-1 and JAM-A. CXCL1, CCL5, CXCL4, CXCL7 and MIF are also implicated in monocyte trafficking into aortas. Recently it has been reported that Ly6C(high) and Ly6C(low) monocyte subsets differently use CCL2, CX3CL1 and CCL5 for their homing into atherosclerotic aortas. T and B lymphocytes constitutively migrate into the normal and atherosclerotic aortic wall in an L-selectin-dependent manner. Recent studies suggest an important role of CCL5, CXCL10, CXCL16, CXCR6 and MIF in T cell influx into the atherosclerotic wall. However, there is little information available on the mechanisms of recruitment of other types of the immune cells such as NK, NKT and mast cells. In this review we shall summarize what is known about leukocyte recruitment into the aortic wall during atherosclerosis with a focus on mouse model systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220701     DOI: 10.2174/138945007783220650

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  50 in total

1.  Transcriptional regulation of beta2-microglobulin demonstrated via a novel genomic and proteomic analysis of percutaneously collected peripheral atheroma.

Authors:  Brian L Stauffer; Erich J Kushner; Ted Wulfman; Thomas Zeller; Rebecca Sobus; Christian M Westby
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

2.  The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment.

Authors:  Matthew J Butcher; Breanne N Gjurich; Tracy Phillips; Elena V Galkina
Journal:  Circ Res       Date:  2012-02-02       Impact factor: 17.367

3.  wRAPping up early monocyte and neutrophil recruitment in atherogenesis via Annexin A1/FPR2 signaling.

Authors:  Matthew J Butcher; Elena V Galkina
Journal:  Circ Res       Date:  2015-02-27       Impact factor: 17.367

Review 4.  Potential contributions of intimal and plaque hypoxia to atherosclerosis.

Authors:  Guo-Hua Fong
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

5.  Flow cytometry analysis of immune cells within murine aortas.

Authors:  Matthew J Butcher; Margo Herre; Klaus Ley; Elena Galkina
Journal:  J Vis Exp       Date:  2011-07-01       Impact factor: 1.355

6.  Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy.

Authors:  Samantha D Smith; Caroline E Dunk; John D Aplin; Lynda K Harris; Rebecca L Jones
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

7.  Chronic discrimination predicts higher circulating levels of E-selectin in a national sample: the MIDUS study.

Authors:  Elliot M Friedman; David R Williams; Burton H Singer; Carol D Ryff
Journal:  Brain Behav Immun       Date:  2009-01-11       Impact factor: 7.217

Review 8.  Non-coding RNA regulation of endothelial and macrophage functions during atherosclerosis.

Authors:  Binod Aryal; Yajaira Suárez
Journal:  Vascul Pharmacol       Date:  2018-03-15       Impact factor: 5.773

9.  CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas.

Authors:  Matthew J Butcher; Chih-I Wu; Tayab Waseem; Elena V Galkina
Journal:  Int Immunol       Date:  2015-11-27       Impact factor: 4.823

Review 10.  Circulating adhesion molecules in obstructive sleep apnea and cardiovascular disease.

Authors:  Victoria M Pak; Michael A Grandner; Allan I Pack
Journal:  Sleep Med Rev       Date:  2013-04-22       Impact factor: 11.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.